🇺🇸 TMDX — TransMedics Group, Inc.

Nombre completo

TransMedics Group, Inc.

Divisa

USD

Mercado

NasdaqGM

Sector

Salud

Industria

Medical Devices

Empleados

898

PER ⓘ

17,27 (puede no estar actualizado)

Dividend yield

0,00% (puede no estar actualizado)

Precio objetivo analistas

98,73 USD (puede no estar actualizado)

Primera cotización

02/05/2019

Precio actualizado

hace 1 día

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.